SmartSpot Quality offers an EQA program for Genotype MTBDRplus & MTBDRsl.
For MTBDRplus, each panel includes 4 DCS consisting of a variety of strains of MTB Rifampicin sensitive, MTB Rifampicin resistant, MTB isoniazid resistant and non-tuberculosis mycobacteria material all of which is inactivated, quantified and intact. In addition, 5 high resolution images of hybridized strips are provided (each with a clinical case history) to further assess the laboratory interpretation of the Assay.
For MTBDRsl, each panel includes 5 high resolution images of hybridized strips for interpretation. We are in the process of developing second line resistance strains for the MTBDRsl Assay and once complete, we will include a DCS component to the MTBDRsl EQA program.
The results for both MTBDRplus and MTBDRsl are reported on our Online Result Reporting Tool, LPAMonitor that automatically generates a report for each successful submission.
The standard submission deadlines are:
- Panel 1: 31 May
- Panel 2: 31 July
- Panel 3: 31 October
Note: For new enrolments, depending on need it is possible to accommodate different submission deadlines.